Bionano reports preliminary Q4 rev $7.9-8.1M (down ~25% YoY); FY rev $30.5-30.7M (down ~15%)

Bionano Genomics, Inc.

2024-FY EPS reported -$88.13 revenue$30,776,000

Preliminary Q4 2024 revenue $7.9-8.1M, down ~25% from Q4 2023 due to discontinued clinical service products.
Full year 2024 revenue $30.5-30.7M, down ~15% from FY2023; excluding discontinued services, core revenue ~$29M, roughly flat.
OGM installed base 371 units at year-end, up 14% from 326 at end of 2023; flowcell sales 8,058, up 1% YoY.
Cash, equivalents and AFS securities $20.9M as of Dec 31, 2024; raised $10M gross via registered direct offering in Jan 2025.
Annualized operating costs reduced by ~$100M since May 2023; senior secured convertible debenture terms modified to lower monthly payments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.